x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011948
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Monkey |
| Applications | WB, IP |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro208 of human cytochrome b protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | MT-CYB |
| UniProt No. | P00156 |
| Gene ID | 4519 |
| Gene Description | Cytochrome b, encoded by the gene MT-CYB, is a subunit of ubiquinol-cytochrome c reductase, also known as cytochrome bc1, or complex III, of the mitochondrial respiratory chain. This protein complex mediates electron transfer from ubiquinol to cytochrome c, contributing to the generation of a proton gradient that powers ATP synthesis. Cytochrome b is an integral membrane protein and notable for being the only protein within complex III that is encoded by the mitochondrial genome. Genetic sequence analyses have identified mutations in MT-CYB that are linked to a variety of diseases and pathologies. Natural variations in the sequence of MT-CYB have also proven highly useful as a tool to determine phylogenetic relationships between organisms. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
